 |
|
|
| |
Effectiveness of the salvage therapy sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in chronic hepatitis C; clinical practice experience from the TRIO network
|
| |
| |
Reported by Jules Levin
EASL 2019 April 10-14 Vienna Austria
Bruce Bacon1, Michael Curry2, Steven L. Flamm3, Scott Milligan4, Naoky Tsai5, Nicole Wick4, Zobair Younossi6 and Nezam Afdhal2
1Saint Louis University School of Medicine, 2Beth Israel Deaconess Medical Center, 3Northwestern University Feinberg School of Medicine, 4Trio Health Analytics, 5University of Hawaii, and 6Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital
|
| |
|
|
|
|
|
